The global arterial cannula market has witnessed remarkable growth, reaching a market value of USD 21 billion in 2023. With a robust compound annual growth rate (CAGR) of 6.6%, this market is ...

A recently published study by FMI expects the global arterial cannula market for arterial cannulas was valued at US$ 21 billion in 2023, and between 2022 to 2033, it is anticipated to grow at a CAGR ...

The arterial cannula (26G BD Neoflon) was connected to an intravenous (IV) tubing (RMS infusion set, Romsons, Agra, India), which was already cut to one-fourth its length, and its volume measured ...

LivaNova PLC announced its Bi-Flow ECMO earned CE Mark for ECMO procedures where femoral artery cannulation can be applied.

BD (BDX) commences the enrollment of the first patient in the IDE study for the assessment of the company's Vascular Covered Stent for the treatment of Peripheral Arterial Disease.

LivaNova PLC today launched its innovative arterial femoral cannula, Bi-Flow, designed to prevent limb ischemia during cardiac surgery.

The usual procedure for a single dialysis calls for either an indwelling arterial cannula or vena-cava catheterization involving surgical cutdowns. 3 This is not a practical approach for multiple ...

Explore key insights on the Arterial Cannula Market, including growth trends, demand drivers, and forecasts from 2023 to 2033. Europe's National Health Strategy aims to reduce cardiovascular risks ...

LivaNova PLC, a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation cannula earned CE Mark approval for ECMO procedures where ...